J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283

Percentage change from baseline in TH and FN BMD at months 12 and 24 was greater (p < 0.05) in ZOL-treated patients compared with placebo in most subgroups. Treatment-by-subgroup interactions (p <  0.05) indicated that a greater effect on BMD was observed for TH BMD at month 12 in females, in patients in the lower tertile body mass index at baseline (≤22.6 kg/m2), and in patients with baseline FN BMD T-score of ≤ –2.5; for FN BMD in patients who received ZOL for >6 weeks post-surgery; and for TH and FN BMD in patients with a history of one or more prior fractures. All interactions were limited to the first 12 months after treatment with none observed for the 24-month comparisons.

Autor: M.JS,OrwigDL,LylesKW,N.L,BoonenS,AdachiJD,RecknorC,Colón-E.CS,M.P,Bucci-RC,SuG,JohnsonR,PieperCF